TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07807163: A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

Sponsor: Bicara Therapeutics · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07807163 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07807163 Rescue Dossier →